Molecules targeting mutant RAS protein

The invention is broadly in the medical field and more specifically concerns molecules directed to mutant human RAS proteins. The disclosed molecules are particularly useful in therapy, such as in methods of treating neoplastic diseases. The application also teaches methods for making and using the disclosed molecules and compositions comprising the molecules.

Octrooi-publicatienummer: WO2021165452

Bron: USPTO,

Jaar aanvraag: 2021

Jaar toekenning: 2022

Jaar van publicatie: 2021

Status: Aangevraagd

Technologiedomeinen: undefined

Gevalideerd voor IOF-sleutel: Ja

Toegewezen aan: Associatie KULeuven